UCB says long-term data shows Cimzia drug is 'well tolerated' |
|
|
|
Published
:
Tue, 22 May 2007 07:52
|
BRUSSELS (Thomson Financial) - Pharmaceutical group UCB SA said long-term data for Cimzia demonstrated that the Crohn's disease drug is 'well-tolerated' with 'long-term response and remission' in patients.At week 80, the study showed that more than 85 pct of the patient subgroup who continuously received Cimzia every four weeks maintained clinical response, with nearly 74 pct of these patients achieving remission, the group said.The patients represented a broad population living with moderate to severe Crohn's disease, including patients who had previously received Centocor Inc's infliximab, those treated with monotherapy, or those treated with immunosuppressants.Crohn's disease is a chronic disorder that causes inflammation of the gastrointestinal tract, most commonly at the end of the small intestine (the ileum) and in the large intestine (the colon).simon.zekaria@thomson.comsz/vsCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
Print this Story
Brussels shares TFN at a glance outlook 